A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX.

Trial Profile

A Prospective Randomized, Open, Multi-Center Trial Comparing TNF-Blockade + MTX to MTX+SSZ+HCQ in Patients With Early RA With an Inadequate Response to MTX.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Infliximab (Primary) ; Hydroxychloroquine; Methotrexate; Sulfasalazine
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SWEFOT
  • Most Recent Events

    • 19 Dec 2016 Results (n=157) assessing multi-biomarker disease activity score in methotrexate inadequate responders, published in the Arthritis and Rheumatology
    • 10 Jun 2016 According to a Crescendo Biologics media release results related to multi-biomarker disease activity score measured by VECTRA DA test will be presented at European League Against Rheumatism (EULAR) meeting.
    • 10 Jun 2016 Results related to multi-biomarker disease activity score measured by VECTRA DA test published in a Crescendo Biologics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top